FindTrial
Sign In

This study is to ascertain the after effects of anesthesia such as nausea and vomiting in patients undergoing a procedure called fundus fluorescein angiography.

Prophylactic intravenous ondansetron for nausea and vomiting in patients undergoing Fundus Fluorescence Angiography.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013304
Enrollment
200
Registered
2018-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intravenous Ondensetron Injection: 8 mg followed by a second dose of 8 mg eight hours later prior to the fundus fluorescein angiography procedure. Control Intervention1: Not applicable:

Sponsors

Giridhar Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who have been advised Fluorescein Angiography procedure.

Exclusion criteria

Exclusion criteria: Patients who have: No diabetic retinopathy No hypertension No retinal vein occlusion No age related macular degeneration No cystoid macular oedema

Design outcomes

Primary

MeasureTime frame
Verbal rating scale measures for nausea and vomitingTimepoint: 12 Months—

Secondary

MeasureTime frame
Other adverse events during FFA Variation in vital parameters during and after the procedure Relation between anxiety level and incidence of nausea and vomiting.Timepoint: 12 Months—

Countries

India

Contacts

Public ContactDr Rameez N Hussain

Giridhar Eye Institute

dr.rameezhussain@gmail.com9444527891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026